Detalhe da pesquisa
1.
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Ann Oncol
; 33(1): 67-79, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562610
2.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Ann Oncol
; 33(11): 1168-1178, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35973665
3.
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Ann Oncol
; 33(1): 57-66, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34624497
4.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Breast Cancer Res Treat
; 175(2): 389-399, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796651
5.
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Ann Oncol
; 29(6): 1409-1416, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29668860
6.
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. / Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib.
Pneumologie
; 72(11): 774-781, 2018 Nov.
Artigo
em Alemão
| MEDLINE | ID: mdl-30408830
7.
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].
Ann Oncol
; 33(4): 454, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086737
8.
[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy]. / Exonabhängige Subgruppenanalyse der nicht-interventionellen REASON-Studie: PFS und OS beim EGFR-mutierten NSCLC mit Behandlung von Gefitinib versus Chemotherapie.
Pneumologie
; 70(8): 514-21, 2016 Aug.
Artigo
em Alemão
| MEDLINE | ID: mdl-27512931
9.
[ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)]. / ALK-Testung beim nicht-kleinzelligen Lungenkarzinom (NSCLC): Immunhistochemie (IHC) und/oder Fluoreszenz-in-situ-Hybridisierung (FISH)?
Pneumologie
; 70(4): 277-81, 2016 Apr.
Artigo
em Alemão
| MEDLINE | ID: mdl-26984109
10.
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.
Ann Oncol
; 24(4): 986-92, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23161898
11.
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
ESMO Open
; 7(1): 100333, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35042152
12.
[Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?]. / Stellungnahme der DGP und der AG Thorakale Onkologie der AG Onkologie/Deutsche Krebsgesellschaft e. V. zur ALK-Testung beim NSCLC: Immunhistochemie und/oder FISH?
Pathologe
; 37(2): 187-91, 2016 Mar.
Artigo
em Alemão
| MEDLINE | ID: mdl-26984297
13.
Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
Pathol Res Pract
; 227: 153651, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34673351
14.
Mature T-lineage leukemia with growth factor-induced multilineage differentiation.
J Exp Med
; 169(3): 1101-20, 1989 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-2538542
15.
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.
Lung Cancer
; 148: 105-112, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871455
16.
T cell receptor gamma and delta rearrangements in hematologic malignancies. Relationship to lymphoid differentiation.
J Clin Invest
; 84(2): 506-16, 1989 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-2547833
17.
The MLL recombinome of acute leukemias.
Leukemia
; 20(5): 777-84, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16511515
18.
ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.).
Lung Cancer
; 103: 1-5, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28024689
19.
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Leukemia
; 19(5): 750-8, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15759031
20.
[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. / Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft--Kurzfassung.
Pneumologie
; 65(8): e51-75, 2011 Aug.
Artigo
em Alemão
| MEDLINE | ID: mdl-21830177